Eloralintide Side Effects: Trial-Reported Rates by Dose Arm (2026)
Reviewed by
Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant
Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.
Eloralintide side effects in the 48-week Phase 2 trial were led by nausea, reported by 32.7% of eloralintide recipients overall against 13.5% on placebo and ranging from 11.1% in the 1 mg arm to 64.3% in the fixed 6 mg arm, followed by fatigue at 26.9% pooled; discontinuation for adverse events was 10.1% across the eloralintide arms against 7.7% on placebo. Every rate on this page is a trial-reported figure by arm.
As of October 2026 eloralintide, Lilly’s once-weekly amylin receptor agonist, remains an investigational molecule with no approval from any regulator (Lilly, What to know about eloralintide). What follows describes what trial participants reported under specific protocols; it is not medical advice, and it does not tell anyone how to manage a symptom.
The page exists because eloralintide side effects are the central question for any laboratory modelling work on the single 10 mg lyophilized eloralintide research vial: the dose schedules that produced the lowest event rates are also the ones a research protocol would copy. The eloralintide research guide sets out the trials themselves; here the focus is on adverse events alone.
Eloralintide Side Effects at a Glance
| Event category | Trial-reported rate | Dataset |
|---|---|---|
| Nausea, pooled eloralintide arms | 32.7% (placebo 13.5%) | Phase 2, 48 weeks, N=260 safety population |
| Nausea range by arm | 11.1% (1 mg) to 64.3% (fixed 6 mg) | Phase 2 |
| Fatigue, pooled | 26.9% (placebo 11.5%) | Phase 2 |
| Discontinued for adverse events, pooled | 10.1% (placebo 7.7%) | Phase 2 |
| Serious adverse events | 5.3% pooled (placebo 5.8%); no deaths | Phase 2 |
| Nausea without any titration | 8% of eloralintide recipients (6 of 73); placebo 0% | Phase 1b, 12 weeks, 1.2 to 12 mg weekly |
| Injection-site reactions | 13.9% to 33.3% across active arms (placebo 3.7%), mostly mild | Phase 1b |
| Mood-related withdrawals | Three, all in the 12 mg cohort, resolved within 2 to 4 days | Phase 1b |
| Single-dose events | GI events in 2 of 36 recipients, all in the 12 mg cohort; no discontinuations | Phase 1 single dose, 0.04 to 12 mg |
Sources: Billings et al., The Lancet 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026; Briere et al., Molecular Metabolism 2025.

Phase 2 Adverse Events by Arm: The Full Table
The 48-week Phase 2 trial (NCT06230523) randomised 263 adults with obesity or overweight and no type 2 diabetes to placebo, four fixed weekly doses or two escalation schedules, and its safety analysis covered 260 participants (Billings et al., The Lancet 2025). Because the arms held only 24 to 54 people, a single additional report shifts a percentage by two to four points, so the eloralintide side effects table below should be read for its pattern rather than its decimals.
| Arm (n) | Nausea | Vomiting | Fatigue | Constipation | Diarrhoea | Discontinued for adverse events |
|---|---|---|---|---|---|---|
| Placebo (53) | 13.5% | 0% | 11.5% | 6% | Not itemised | 7.7% |
| 1 mg fixed (28) | 11.1% | 0% | 0% | 15–17% | Not itemised | 11.1% |
| 3 mg fixed (24) | 13.0% | 0% | 13.0% | 15–17% | Not itemised | 0% |
| 6 mg fixed (28) | 64.3% | 25.0% | 28.6% | Not itemised | Not itemised | 21.4% |
| 9 mg fixed (54) | 33.3% | 11.1% | 42.6% | 24.1% | 11.1% | 7.4% |
| 6→9 mg escalation (24) | 54.2% | 12.5% | 45.8% | 16.7% | 12.5% | 8.3% |
| 3→6→9 mg escalation (52) | 25.0% | 1.9% | 21.2% | 7.7% | 17.3% | 11.5% |
| All eloralintide arms pooled | 32.7% | 8.2% | 26.9% | — | — | 10.1% |
Source: Billings et al., The Lancet 2025 (safety population N=260). Serious adverse events: 5.8% placebo, 5.3% pooled eloralintide, no deaths. Any-cause discontinuation ranged from 14.8% to 46.4% across eloralintide arms against 35.8% on placebo.
Lilly’s own description of the eloralintide side effects profile is brief: “The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, which were seen more frequently in the higher dose arms,” with incidence lower under slower escalation and similar to placebo in the 1 mg and 3 mg arms (Lilly press release, Nov 6, 2025). The table bears that out at the low end, where nausea at 1 and 3 mg (11.1% and 13.0%) did not exceed placebo (13.5%) and vomiting was absent.
The fixed 6 mg arm is the outlier, with 64.3% nausea, 25.0% vomiting and 21.4% discontinuation for adverse events, all worse than the fixed 9 mg arm (33.3%, 11.1% and 7.4%). With 28 people in the arm, noise is a more economical explanation than an inverted dose response. Fatigue, by contrast, rose steadily with dose, from 0% at 1 mg to 42.6% at fixed 9 mg and 45.8% in the 6→9 mg arm, and even the slow-escalation arm reported it in 21.2%.

How the Escalation Schedule Changed the Rates
Three arms reached 9 mg by different routes, and the eloralintide side effects differ markedly between them. Fixed 9 mg from week one gave 33.3% nausea, 11.1% vomiting, 24.1% constipation and 42.6% fatigue. The 6→9 mg arm, which held 6 mg for 20 weeks before 28 weeks at 9 mg, gave 54.2% nausea and 45.8% fatigue. The 3→6→9 mg arm, which spent four weeks at 3 mg and four at 6 mg before 40 weeks at 9 mg, gave 25.0% nausea, 1.9% vomiting, 7.7% constipation and 21.2% fatigue.
That gentler profile had a cost on both sides of the ledger. The 3→6→9 mg arm produced the smallest weight change of the three (−16.4% against −20.1% for fixed 9 mg and −19.9% for 6→9 mg, efficacy estimand, Lilly press release), and its discontinuation for adverse events (11.5%) was higher than fixed 9 mg’s 7.4%. Diarrhoea ran the other way too, at 17.3% in the slow arm against 11.1% and 12.5% in the other two.
The reading that survives those cross-currents is that stepping through 3 and 6 mg lowered four of the main eloralintide side effects, nausea, vomiting, constipation and fatigue, relative to starting at a higher dose, without lowering every event and without matching fixed 9 mg on weight. The eloralintide dosage guide gives the week-by-week schedules and the vial arithmetic for each route.
Twelve Weeks Without Titration: The Phase 1b Profile
Before Phase 2, Part B of NCT05295940 gave 100 participants 12 weeks of weekly eloralintide or placebo with no dose titration, starting directly at 1.2, 3, 6 or 12 mg (placebo 27; 1.2 mg 8; 3 mg 6; 6 mg 23; 12 mg 36), followed by roughly 10 weeks off drug (Bhattachar et al., Diabetes, Obesity and Metabolism 2026). Starting at the full dose makes this the sternest test of eloralintide side effects yet run.
| Phase 1b event (12 weeks, no titration) | Eloralintide recipients (n=73) | Placebo (n=27) |
|---|---|---|
| Nausea | 8% (6 of 73); 13.0% at 6 mg, 8.3% at 12 mg, none at 1.2 or 3 mg | 0% |
| Diarrhoea | 10% (7 of 73) | 0% |
| Vomiting | 4% (3 of 73) | 0% |
| Decreased appetite (most common event) | 19.2% | Not itemised |
| Headache | 12.3% | Not itemised |
| Fatigue | 11.0% | Not itemised |
| Injection-site reactions | 13.9% to 33.3% across active arms, mostly mild | 3.7% |
| Discontinued for adverse events | 11 participants, including 2 depressed mood, 1 persistent depressive disorder, 1 somnolence, 1 decreased appetite | Not itemised |
| Discontinued for nausea, vomiting or diarrhoea | None | None |
| Serious adverse events on drug | One (acute kidney injury at 6 mg, judged unrelated) | Not itemised |
Source: Bhattachar et al., Diabetes, Obesity and Metabolism 2026 (Part B of NCT05295940; 100 randomised; three US centres).
Two features of this dataset are easy to misread. Nausea at 8% without any titration looks far better than the Phase 2 pooled 32.7%, but the studies differ in length (12 against 48 weeks), population (73 eloralintide recipients against a 260-person safety population) and dose set, so the gap is not evidence that titration made things worse. Injection-site reactions, 13.9% to 33.3% against 3.7% on placebo, were common but mostly mild; the subcutaneous versus intramuscular injection guide covers the route.
Mood Events at 12 mg and the Single-Dose Study
The eloralintide side effects that attract the most attention are the three mood-related withdrawals in Phase 1b: two for depressed mood and one for persistent depressive disorder, all in the 12 mg cohort, all resolving within 2 to 4 days of stopping, with one further mild depressed-mood event at 6 mg that did not lead to withdrawal. Twelve milligrams weekly is above the highest Phase 2 dose of 9 mg and was not carried into any later trial.
Part A, the single-dose study, adds the earliest data. Among 48 healthy participants given one subcutaneous dose of 0.04 to 12 mg, gastrointestinal events occurred in only 2 of 36 eloralintide recipients, and nausea, vomiting, dyspepsia, decreased appetite and the single injection-site reaction were all confined to the six people in the 12 mg cohort; there were no discontinuations and no serious adverse events (Briere et al., Molecular Metabolism 2025).
Taken together, the Phase 1 program places its most-cited events above the Phase 2 dose ceiling: the mood withdrawals, the single-dose GI events and the single-dose injection-site reaction all sit at 12 mg. That is not proof that 9 mg is free of them; it is a description of where the events occurred, and 12 mg appears in no later trial.

Nausea Next to Cagrilintide and Semaglutide
The obvious question is whether eloralintide side effects are milder than those of the other amylin analogue, cagrilintide, or of a GLP-1 agonist such as semaglutide. No head-to-head trial exists, so the only honest table lists each drug’s own placebo-controlled figures with their duration and warns that they cannot be ranked.
| Trial | Duration and population | Nausea or GI measure | Placebo |
|---|---|---|---|
| Eloralintide Phase 2 (Billings et al. 2025) | 48 weeks; 263 adults without type 2 diabetes | Nausea 32.7% pooled; 11.1% to 64.3% by arm; 25.0% in the 3→6→9 mg arm | 13.5% |
| Cagrilintide Phase 2 (Lau et al. 2021) | 26 weeks; 706 adults with overweight or obesity; 0.3 to 4.5 mg weekly | Nausea 20% to 47%, highest at 4.5 mg; constipation 8% to 21%; injection-site reactions 4% to 12% | 18% |
| Semaglutide STEP 1 (Wilding et al. 2021) | 68 weeks; 1,961 participants; 2.4 mg weekly | Nausea 44.1%; discontinuation for gastrointestinal events 4.5% | 17.4% nausea; 0.8% GI discontinuation |
Sources: Billings et al., The Lancet 2025; Lau et al., The Lancet 2021; Wilding et al., N Engl J Med 2021. Separate trials; not head-to-head.
Three details keep the table from supporting a ranking. Cagrilintide’s placebo nausea (18%) was higher than eloralintide’s (13.5%), its trial was little more than half the length, and its 20% to 47% is a range across five doses in a 706-person study rather than a per-arm figure from arms of 24 to 54 (Lau et al., The Lancet 2021). Semaglutide’s 44.1% nausea against 17.4% on placebo came over 68 weeks, the longest of the three trials (Wilding et al., N Engl J Med 2021).
Lilly’s hypothesis is that eloralintide’s AMY1R preference improves tolerability relative to a non-selective amylin agonist, but the trial record cannot test it; the receptor data behind that hypothesis are in our eloralintide research guide, and the CagriSema vs semaglutide comparison covers cagrilintide’s combination with a GLP-1 agonist.
What the Data Do Not Yet Show
Several gaps limit what can be said about eloralintide side effects as of October 2026. No monotherapy data extend beyond 48 weeks, so nothing is known about events in a second year of dosing. The Phase 2 arms held 24 to 54 people, which is why fixed 6 mg can look worse than fixed 9 mg. And the monotherapy trials had no active comparator arm, so there is no within-trial reference drug for any of the rates.
Lilly’s page states that the company “is currently investigating eloralintide in Phase 3 trials,” and no Phase 3 doses, readout dates or filing timeline have been disclosed. Until those trials report, the eloralintide side effects profile rests on 260 Phase 2 participants, 100 Phase 1b participants and 48 single-dose participants, and every percentage above carries that denominator.
What the Rates Imply for a Research Protocol
For laboratory work that models the trials, the eloralintide side effects data point to one design choice above all. Among the arms that reached 9 mg, 3→6→9 mg (3 mg for four weeks, 6 mg for four weeks, then 9 mg) had the lowest nausea, vomiting, constipation and fatigue, and the fixed 1 and 3 mg arms stayed at placebo-level nausea for 48 weeks.
A protocol built on those schedules has a published 48-week tolerability record. One starting at 12 mg has only 12 weeks of data, and one starting at a fixed 6 mg inherits the worst-tolerated Phase 2 arm as its reference.
The Phase 1b injection-site rate argues for recording the site at every dose and rotating it, and the mood events at 12 mg argue for keeping any modelled dose within the 1 to 9 mg Phase 2 range. From a 10 mg vial reconstituted with 1.0 mL of bacteriostatic water (10 mg/mL), the 3→6→9 mg schedule draws 30, 60 and 90 units on a U-100 insulin syringe; the eloralintide reconstitution guide and the peptide storage guide cover handling.

The 10 mg Eloralintide Research Vial
PSPeptides supplies eloralintide as a single 10 mg lyophilized vial, synthesized in a cGMP-compliant facility in Temecula, California, with every lot tested by independent accredited laboratories for HPLC purity at a 99%+ minimum, mass-spectrometry identity, endotoxin, sterility, heavy metals and fentanyl, as set out on the certifications page; each lot’s certificate of analysis is published on the eloralintide product page with current pricing.
The free peptide calculator converts any dose in the eloralintide side effects tables above into syringe units, and bacteriostatic water and U-100 insulin syringes can be added to the same order. Orders placed before 2 PM EST ship the same day, US shipping is free, and cards, Afterpay and Klarna are accepted.
Frequently Asked Questions on Eloralintide Tolerability
Does eloralintide cause less nausea than cagrilintide?
No trial has compared them, so the question has no direct answer. Eloralintide’s Phase 2 reported nausea in 32.7% of recipients pooled (11.1% to 64.3% by arm) against 13.5% on placebo over 48 weeks, while cagrilintide’s Phase 2 reported 20% to 47% against 18% on placebo over 26 weeks, and those figures come from different trials, durations and arm sizes.
Why was fatigue common in the eloralintide trial?
The trial reports the rates but not a mechanism. Fatigue rose with dose, from 0% at 1 mg and 13.0% at 3 mg to 42.6% at fixed 9 mg and 45.8% in the 6→9 mg arm, against 11.5% on placebo, and the slow 3→6→9 mg escalation held it to 21.2%.
Did anyone stop eloralintide because of nausea?
In the 12-week Phase 1b study nobody discontinued for nausea, vomiting or diarrhoea despite starting at full dose without titration. In Phase 2, discontinuation for adverse events of any kind ranged from 0% in the 3 mg arm to 21.4% in the fixed 6 mg arm, with 10.1% pooled against 7.7% on placebo.
What were the most serious adverse events reported for eloralintide?
Serious adverse events occurred in 5.3% of pooled eloralintide participants against 5.8% on placebo in Phase 2, with no deaths. In Phase 1b the single serious event on drug was an acute kidney injury at 6 mg judged unrelated, and three participants in the 12 mg cohort withdrew for mood-related events that resolved within 2 to 4 days.
References
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
- Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
- Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 2026;28(4):2651–2660. https://doi.org/10.1111/dom.70439
- Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. https://doi.org/10.1016/j.molmet.2025.102271
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)01751-7
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2032183
- Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
All PSPeptides products are sold exclusively for research and laboratory use.